Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors

NCT05269381 · clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
RECRUITING
Status
132
Enrollment
OTHER
Sponsor class

Conditions

Interventions

Sponsor

Mayo Clinic